Company profile_SinoBioPrint (Shanghai) Biotech Ltd.

Company Profile

　　SinoBioPrint (Shanghai) Biotech Ltd. was established in July 2018; Mainly engaged in the research and development, clinical transformation of stem cell and biological 3D printing in the field of regenerative medicine, and the standardization and large-scale production of biological 3D printing materials (biological ink). Huaxia Siyin has established three cGMP production lines of bio-ink, stem cell and bio-3D printing in Pujiang Zhigu.

　　SinoBioPrint takes the stem cell and biological 3D printing technology originated from Harvard University as the core platform, and the bio-inks developed and produced by ourselves as the core material, including LAP blue light initiator, GelMA, HAMA, CSMA and more than 10 kinds of bio-inks, which have reached the international leading level in product quality, variety and batch yield. Independently developed and carried out a number of clinical projects of medical devices, including biological 3D printing gun, cartilage regeneration hydrogel, bone cartilage 3D printing scaffold and hip cartilage lining living graft, etc

　　SinoBioPrint focuses on the field of tissue engineering cartilage regeneration, has accumulated some experience in cartilage biomechanical testing methods, and made some special fixtures. We are willing to work with fellow experts and professors to establish new methods of cartilage mechanics testing, and also willing to provide cartilage biomechanical testing services for researchers or enterprises in need.
　　SinoBioPrint has established strategic partnership with well-known bio-3D printing companies such as Shangpu Boyuan, Cyfointelligence and Beao Road. Research partners include Harvard University, Institute of Nanotechnology, Chinese Academy of Sciences, Tsinghua University, Peking University, Zhejiang University, Sichuan University and other domestic and foreign universities and research institutes, as well as Peking University Hospital, West China Hospital, Beijing Plastic Surgery Hospital, Shanghai Ninth Hospital, Shanghai Pulmonary Hospital, Jiangsu Provincial People's Hospital and other domestic third-class hospitals; And to provide partners with bio-ink products and research and development outsourcing services.
　　Focus on bionics, clinical transformation; pursue innovation and benefit the public.

陈慧敏 MD, PhD

SinoBioPrint (Shanghai) Biotech Ltd. CEO